Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
Abstract The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) t...
Saved in:
| Main Authors: | Manabu Shiozawa, Yu Sunakawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-54460-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delving deeper to come back stronger
by: Iain MacRitchie
Published: (2020-11-01) -
MAPEX: look deeper, looking away
by: Ramón Morillo Verdugo, et al.
Published: (2015-07-01) -
Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report
by: Hua-Yang Pang, et al.
Published: (2025-01-01) -
Editorial: Diving deeper with metabolomics into animal physiology
by: Dagnachew Hailemariam, et al.
Published: (2024-11-01) -
Editorial: Digging deeper: understanding root-pathogen interactions
by: Chun Sui, et al.
Published: (2025-01-01)